Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideho Okada

Showing results (11-20 of 187) with videos related to

Pageof 19
Sort By:
Journal of Clinical Immunology|March 29, 2012
Type17 T-cells in central nervous system autoimmunity and tumorsHideho Okada, Samia J Khoury
Expert Review of Neurotherapeutics|May 5, 2011
Do we need novel radiologic response criteria for brain tumor immunotherapy?Hideho Okada, Ian F Pollack
Expert Opinion on Biological Therapy|October 6, 2004
Cytokine gene therapy for malignant gliomaHideho Okada, Ian F Pollack
Neuro-Oncology|September 7, 2017
Is the immune response a friend or foe for viral therapy of glioma?Hideho Okada, Stephen H Thorne
Neuro-Oncology|October 31, 2015
Principles of immunology and its nuances in the central nervous systemGavin P Dunn, Hideho Okada
Journal of Neuro-Oncology|February 25, 2015
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trialsDavid A Reardon, Hideho Okada
Cancer Immunology, Immunotherapy : CII|June 1, 2014
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cellsAkemi Kosaka, Takayuki Ohkuri, Hideho Okada
Japanese Journal of Clinical Oncology|September 28, 2020
The current state of immunotherapy for primary and secondary brain tumors: similarities and differencesTakahide Nejo, Abigail Mende, Hideho Okada
Neuro-Oncology Practice|October 5, 2020
Introduction to immunotherapy for brain tumor patients: challenges and future perspectivesMegan L Montoya, Noriyuki Kasahara, Hideho Okada
Neuro-Oncology|April 30, 2025
The TCR Repertoire: A Window Into Pediatric Brain Tumor ImmunityTakahide Nejo, Robert M Prins, Hideho Okada
Pageof 19

Showing results (11-20 of 187) with videos related to

Sort By:
Pageof 19
Journal of Clinical Immunology|March 29, 2012
Type17 T-cells in central nervous system autoimmunity and tumorsHideho Okada, Samia J Khoury
Expert Review of Neurotherapeutics|May 5, 2011
Do we need novel radiologic response criteria for brain tumor immunotherapy?Hideho Okada, Ian F Pollack
Expert Opinion on Biological Therapy|October 6, 2004
Cytokine gene therapy for malignant gliomaHideho Okada, Ian F Pollack
Neuro-Oncology|September 7, 2017
Is the immune response a friend or foe for viral therapy of glioma?Hideho Okada, Stephen H Thorne
Neuro-Oncology|October 31, 2015
Principles of immunology and its nuances in the central nervous systemGavin P Dunn, Hideho Okada
Journal of Neuro-Oncology|February 25, 2015
Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trialsDavid A Reardon, Hideho Okada
Cancer Immunology, Immunotherapy : CII|June 1, 2014
Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cellsAkemi Kosaka, Takayuki Ohkuri, Hideho Okada
Japanese Journal of Clinical Oncology|September 28, 2020
The current state of immunotherapy for primary and secondary brain tumors: similarities and differencesTakahide Nejo, Abigail Mende, Hideho Okada
Neuro-Oncology Practice|October 5, 2020
Introduction to immunotherapy for brain tumor patients: challenges and future perspectivesMegan L Montoya, Noriyuki Kasahara, Hideho Okada
Neuro-Oncology|April 30, 2025
The TCR Repertoire: A Window Into Pediatric Brain Tumor ImmunityTakahide Nejo, Robert M Prins, Hideho Okada
Pageof 19